

27.08.2026

18:00 – 19:30 SGT (Singapore)
14:00 – 15:30 GST (Dubai/UAE)
12:00 –13:30 CEST (Central Europe)

MphaR Virtual Platform
As the understanding of ESR1 mutations (ESR1m) continuesto evolve, integrating molecular testing into clinical decision-making isbecoming increasingly important in the management of HR+/HER2− metastaticbreast cancer.This educational webinar aims to provide practical insights intocurrent evidence, testing approaches, and real-world considerations forimplementing ESR1m testing in routine practice.
Abbreviations: ctDNA, circulating tumor DNA;ESR1, estrogen receptor 1; ESR1m, estrogen receptor 1 mutation(s); HR+/HER2−,hormone receptor-positive/human epidermal growth factor receptor 2-negative
Thank you! Your registration has been confirmed. We look forward to your participation. You will soon receive additional information, including instructions on how to access the platform and join the webinar. If you have any questions, please contact us at virtualplatform@m-phar.com.
Proprietary and confidential © AstraZeneca 2026. Not for further distribution.This Educational Webinar is organized and funded by AstraZeneca for invited healthcare professionals (HCPs) only.
VEEVA ID: ZX-XXXX | DOP: July 2026
